EEF2K and breast carcinoma: In this study, we sought the effect of eEF2 K-siRNA by supporting quercetin (QU) molecules, known as a chemotherapeutic agent in a novel hybrid nanoparticle (HNP) developed as applying LbL method, on TNBC-type breast cancer (Fig. 1).